What Is Retatrutide?
TL;DR: Retatrutide is an investigational weight-loss drug that activates three separate hormone receptors (GLP-1, GIP, and glucagon) and produced the largest average weight loss of any incretin-based drug tested in a randomized trial so far — but it’s still in clinical trials, not an approved medication.
Retatrutide (Eli Lilly’s LY3437943) is often described as the “triple G” drug because it activates three receptors involved in metabolism: GLP-1 and GIP, the same two targeted by tirzepatide (Mounjaro/Zepbound), plus the glucagon receptor. That third target is what’s generating so much attention in weight-management and biohacking communities — it’s the first mechanism proposed to meaningfully beat tirzepatide’s results in head-to-head-style trial comparisons.
How It Works
GLP-1 and GIP receptor activation work the way they do in semaglutide and tirzepatide — slowing digestion and reducing appetite. Adding glucagon receptor activation is believed to increase energy expenditure on top of that appetite effect, a combination that researchers think explains why trial participants lost more weight, on average, than has been reported for GLP-1-only or dual-agonist drugs.
Current Status
This is the single most important thing to understand about retatrutide: it is not an approved drug. It’s a promising trial compound with strong early data, but it hasn’t gone through the full regulatory process that Ozempic, Wegovy, Mounjaro, and Zepbound have. Anyone considering it today is choosing between waiting for trial results and eventual approval, trying to join an active clinical trial, or accepting the real uncertainty of unregulated research-chemical sourcing.